Lexaria Bioscience Corp. (OTCMKTS:LXRP) is the company behind the proprietary drug delivery technology, DehydraTECH™. The technology licensed to multiple companies in the cannabis industry is used alongside cannabinoid beverages and different ingestible product formats. The technology’s primary role is to enhance the delivery of active pharmaceutical ingredients (APIs), which must be in low dosage.
The company says that through the use of cannabidiol formulated together with the patented technology; it will be carrying out an exploratory clinical study. The aim is to evaluate the reduction of blood pressure in volunteers with pre- or mild hypertension. This has received an endorsement from the Ethics board.
The Study is Likely to Be of Interest to Potential Future Pharmaceutical Partners
This is a new study, which will get many by surprise because Lexaria did not disclose it. It will enroll 24 volunteers, 12 males and 12 females, all aged 45-70 years. They will each receive a 300 mg dose of CBD with or without DehydraTECHTM formulation across two separate study visits. Both primary and secondary outcomes will be considered in picking out the key inflammatory indicators allied to cardiovascular disease.
The study should complement a previous one conducted in 2018, according to the CEO of Lexaria, Chris Bunka. He explained, “…Positive results in this study are expected to be of particular interest to the antihypertensive products sector that is valued at over $22 billion.”
Additionally, it will help the company strengthen its value proposition as it seeks out more partnership opportunities for its technology within the pharmaceutical industry.
Lexaria is a Global Leader In Improving The Speed And Efficiency Of Orally-Delivered Drugs
Since it started developing DehydraTECH™ technology in 2014, Lexaria has continued to thrive in its operations. This has been demonstrated through the success of its four wholly-owned subsidiary companies, all of which empowered with global exclusive licenses.
It is worth noting that more than 1billion people globally suffer from hypertension. Sadly, only 13% of them can put their condition under control. On the other hand, despite all the drug therapies, there are for hypertension, a majority of them are said to have a host of unwanted side effects such as reduced kidney function and other gastrointestinal issues.
3 Big Biotech Disruptors For 2021
Post Views: 19,797
Post Views: 69,478 CBD market growth over the next ten years will outpace marijuana growth by more than 30-to-one By...
Stem Holdings Inc (OTCMKTS:STMH) Reports A Growth Of 960% In Q3 2020: Unveils TJGardens Branded Tinctures
Post Views: 1,379 Stem Holdings Inc (OTCMKTS:STMH) posted an increase of 960% YoY to $6.7 million in Q3 2020. It...
Indiva Ltd (OTCMKTS:NDVAF) Signs Three Provincial Agreements: Expands Distribution Network To Eight Provinces: Reports A Robust Growth Of 1273.7% In Q2 2020 Revenues
Post Views: 1,306 Indiva Ltd (OTCMKTS:NDVAF) posted a robust growth of 1273.7% YoY to CAD 2.826 million in revenues in...
4Front Ventures Corp (OTCMKTS:FFNTF) Receives Approval From CCC For Mission Dispensary and Cultivation Facilities In Worcester: Will Commence Adult-Use Cannabis Sales
Post Views: 1,317 CCC (Cannabis Control Commission) in Massachusetts approved cultivation and processing facilities and Mission Dispensary of 4Front Ventures...
Pure Sunfarms, A Joint Venture Of Village Farms International Inc (NASDAQ:VFF), Ships Bottled Oil Products TO British Columbia
Post Views: 1,416 Pure Sunfarms, which is a Village Farms International Inc (NASDAQ:VFF) JV, commenced shipment of Cannabis 2.0 products...